News
The new lawsuit repeats those concerns, alleging that Kennedy and other political appointees at the U.S. Department of Health ...
Epstein ‘client list’ doesn’t exist, Justice Department says, walking back theory Bondi had promoted
The acknowledgment that the well-connected Epstein did not have a list of clients to whom underage girls were trafficked ...
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...
A 27-year-old man was killed Monday after opening fire at a U.S. Border Patrol facility in McAllen, Texas, authoriti ...
As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP ...
THE WHAT? A U.S. federal judge has upheld the FDA’s decision to remove semaglutide, the active ingredient in Ozempic and Wegovy, from the drug shortage list—blocking compounding pharmacies from ...
Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results